乌司他丁联合奥曲肽对重症急性胰腺炎患者消化功能和炎性因子的影响
|
摘要
目的探讨乌司他丁联合奥曲肽对重症急性胰腺炎(SAP)患者消化功能和炎性因子的影响。方法选择2016年1月~2017年1月本院接诊的90例SAP患者作为研究对象,根据治疗方法的不同随机均分为观察组和对照组,每组45例。对照组给予奥曲肽治疗,观察组给予奥曲肽联合乌司他丁治疗。比较两组患者的临床疗效,评价两组患者治疗前后消化功能,炎性因子水平变化。结果对照组临床治疗总有效率为80.00%,明显低于观察组的95.56%,组间比较差异具有统计学意义(P<0.05)。治疗后,两组患者的TPG-2、PAMY和LPS水平均下降,CRP、TNF-α、IL-6和IL-10水平均下降,且观察组均低于对照组。两组患者治疗后的消化功能、炎性因子变化水平差异具有统计学意义(P<0.05)。结论乌司他丁联合奥曲肽治疗可显著提升SAP患者临床疗效,改善消化功能,降低炎性因子水平,值得临床推广应用。
Objective To investigate the effects of ulinastatin combined with octreotide on digestive function and inflammatory factors in patients with severe acute pancreatitis(SAP). Methods 90 cases of SAP patients received from January 2016 to January 2017 in our hospital were selected as the subjects. According to the different treatment methods, the patients were randomly divided into the observation group and the control group. The control group was treated with octreotide, and the observation group was treated with octreotide and ulinastatin. The clinical effects of the two groups were compared, and the changes of digestive function and inflammatory factors were evaluated before and after treatment in the two groups. Results The total effective rate of clinical treatment in the control group was 80.00%, which was significantly lower than that of the observation group 95.56%, and the difference between the groups was statistically significant(P<0.05). After treatment, the levels of TPG-2, PAMY and LPS in the two groups were all decreased, and the levels of CRP, TNF-α, IL-6 and IL-10 were all decreased, and the observation group were all lower than those of the control group. The difference of the level of digestive function and inflammatory factors after treatment in the two groups was statistically significant(P<0.05). Conclusion Ulinastatin combined with octreotide can significantly improve the clinical efficacy of SAP patients, improve the digestive function and reduce the level of inflammatory factors. It is worthy of clinical application.
Objective To investigate the effects of ulinastatin combined with octreotide on digestive function and inflammatory factors in patients with severe acute pancreatitis(SAP). Methods 90 cases of SAP patients received from January 2016 to January 2017 in our hospital were selected as the subjects. According to the different treatment methods, the patients were randomly divided into the observation group and the control group. The control group was treated with octreotide, and the observation group was treated with octreotide and ulinastatin. The clinical effects of the two groups were compared, and the changes of digestive function and inflammatory factors were evaluated before and after treatment in the two groups. Results The total effective rate of clinical treatment in the control group was 80.00%, which was significantly lower than that of the observation group 95.56%, and the difference between the groups was statistically significant(P<0.05). After treatment, the levels of TPG-2, PAMY and LPS in the two groups were all decreased, and the levels of CRP, TNF-α, IL-6 and IL-10 were all decreased, and the observation group were all lower than those of the control group. The difference of the level of digestive function and inflammatory factors after treatment in the two groups was statistically significant(P<0.05). Conclusion Ulinastatin combined with octreotide can significantly improve the clinical efficacy of SAP patients, improve the digestive function and reduce the level of inflammatory factors. It is worthy of clinical application.
引文
[1]王琼,杨晓钟,戴伟杰,等.重症急性胰腺炎患者腹腔感染病原菌分布与危险因素分析[J].中华医院感染学杂志,2015,25(23):5346-5348.
[2]王贵良,邱萍,徐林芳,等.生长抑素联用丹参或乌司他丁治疗重症急性胰腺炎疗效观察[J].重庆医学,2016,45(6):731-733.
[3]汪聪,张烨,陈灿兵.生长抑素联合乌司他丁治疗重症胰腺炎的临床效果观察[J].当代医学,2017,23(21):127-128.
[4]游扬,杨歆,常杏,等.腺苷酸活化蛋白激酶在重症急性胰腺炎大鼠肠黏膜屏障损伤机制中的作用[J].第三军医大学学报,2016,38(9):975-981.
[5]岳云霄,余守雅.血必净注射液治疗重症急性胰腺炎的临床效果[J].当代医学,2016,22(29):140-141.
[6]徐益萍,骆方军,郑军,等.重症急性胰腺炎患者血清降钙素原与C-反应蛋白测定的临床价值[J].中华医院感染学杂志,2017,27(5):1089-1092.
[7]阚娜,黄泽健.重症急性胰腺炎继发胰腺感染的相关危险因素分析[J].中国卫生统计,2016,33(1):73-74.
[8]张红松,冯芳,付丽彬,等.不同炎性因子对重症急性胰腺炎的预测价值研究[J].中国全科医学,2017,20(25):3127-3131.
[9]彭玄杰,黄慧峰,陈文晓,等.异甘草酸镁对重症急性胰腺炎患者的临床疗效研究[J].中国临床药理学杂志,2015,31(14):1387-1389.
[10]高建波,唐卫东.通腑清胰方辅助治疗重症急性胰腺炎的临床疗效及对肠道黏膜屏障功能和免疫功能的影响[J].中药材,2015,38(7):1546-1549.
[11]饶平.血液滤过联合持续区域动脉灌流对重症急性胰腺炎治疗效果的影响[J].实用医学杂志,2015,31(14):2334-2337.
[2]王贵良,邱萍,徐林芳,等.生长抑素联用丹参或乌司他丁治疗重症急性胰腺炎疗效观察[J].重庆医学,2016,45(6):731-733.
[3]汪聪,张烨,陈灿兵.生长抑素联合乌司他丁治疗重症胰腺炎的临床效果观察[J].当代医学,2017,23(21):127-128.
[4]游扬,杨歆,常杏,等.腺苷酸活化蛋白激酶在重症急性胰腺炎大鼠肠黏膜屏障损伤机制中的作用[J].第三军医大学学报,2016,38(9):975-981.
[5]岳云霄,余守雅.血必净注射液治疗重症急性胰腺炎的临床效果[J].当代医学,2016,22(29):140-141.
[6]徐益萍,骆方军,郑军,等.重症急性胰腺炎患者血清降钙素原与C-反应蛋白测定的临床价值[J].中华医院感染学杂志,2017,27(5):1089-1092.
[7]阚娜,黄泽健.重症急性胰腺炎继发胰腺感染的相关危险因素分析[J].中国卫生统计,2016,33(1):73-74.
[8]张红松,冯芳,付丽彬,等.不同炎性因子对重症急性胰腺炎的预测价值研究[J].中国全科医学,2017,20(25):3127-3131.
[9]彭玄杰,黄慧峰,陈文晓,等.异甘草酸镁对重症急性胰腺炎患者的临床疗效研究[J].中国临床药理学杂志,2015,31(14):1387-1389.
[10]高建波,唐卫东.通腑清胰方辅助治疗重症急性胰腺炎的临床疗效及对肠道黏膜屏障功能和免疫功能的影响[J].中药材,2015,38(7):1546-1549.
[11]饶平.血液滤过联合持续区域动脉灌流对重症急性胰腺炎治疗效果的影响[J].实用医学杂志,2015,31(14):2334-2337.